These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30016475)

  • 1. Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.
    Tabor DE; Oganesyan V; Keller AE; Yu L; McLaughlin RE; Song E; Warrener P; Rosenthal K; Esser M; Qi Y; Ruzin A; Stover CK; DiGiandomenico A
    J Infect Dis; 2018 Nov; 218(12):1983-1994. PubMed ID: 30016475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.
    Thaden JT; Keller AE; Shire NJ; Camara MM; Otterson L; Huband M; Guenther CM; Zhao W; Warrener P; Stover CK; Fowler VG; DiGiandomenico A
    J Infect Dis; 2016 Feb; 213(4):640-8. PubMed ID: 26333940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.
    Ali SO; Yu XQ; Robbie GJ; Wu Y; Shoemaker K; Yu L; DiGiandomenico A; Keller AE; Anude C; Hernandez-Illas M; Bellamy T; Falloon J; Dubovsky F; Jafri HS
    Clin Microbiol Infect; 2019 May; 25(5):629.e1-629.e6. PubMed ID: 30107283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of
    Long MB; Gilmour A; Kehl M; Tabor DE; Keller AE; Warrener P; Gopalakrishnan V; Rosengren S; Crichton ML; McIntosh E; Giam YH; Keir HR; Brailsford W; Hughes R; Belvisi MG; Sellman BR; DiGiandomenico A; Chalmers JD
    Am J Respir Crit Care Med; 2024 Jul; 210(1):35-46. PubMed ID: 38754132
    [No Abstract]   [Full Text] [Related]  

  • 5. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.
    Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116
    [No Abstract]   [Full Text] [Related]  

  • 6. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
    DiGiandomenico A; Keller AE; Gao C; Rainey GJ; Warrener P; Camara MM; Bonnell J; Fleming R; Bezabeh B; Dimasi N; Sellman BR; Hilliard J; Guenther CM; Datta V; Zhao W; Gao C; Yu XQ; Suzich JA; Stover CK
    Sci Transl Med; 2014 Nov; 6(262):262ra155. PubMed ID: 25391481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia.
    Lopes JA; Garnier NE; Pei Y; Yates JGE; Campbell ESB; Goens MM; Hughes ME; Rghei AD; Stevens BAY; Guilleman MM; Thompson B; Khursigara CM; Susta L; Wootton SK
    Gene Ther; 2024 Jul; 31(7-8):400-412. PubMed ID: 38678160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivirulence Bispecific Monoclonal Antibody-Mediated Protection against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Aguiar-Alves F; Le HN; Tran VG; Gras E; Vu TTT; Dong OX; Quetz JS; Cheng LI; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0202221. PubMed ID: 34902264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models.
    Le HN; Tran VG; Vu TTT; Gras E; Le VTM; Pinheiro MG; Aguiar-Alves F; Schneider-Smith E; Carter HC; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160288
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy.
    Lynch SV; Flanagan JL; Sawa T; Fang A; Baek MS; Rubio-Mills A; Ajayi T; Yanagihara K; Hirakata Y; Kohno S; Misset B; Nguyen JC; Wiener-Kronish JP
    Microb Pathog; 2010 Jun; 48(6):197-204. PubMed ID: 20211240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
    Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A
    Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PcrV titers in non-cystic fibrosis patients with Pseudomonas aeruginosa respiratory tract infection.
    Nagaoka K; Yamashita Y; Kimura H; Kimura H; Suzuki M; Fukumoto T; Hayasaka K; Yoshida M; Hara T; Maki H; Ohkawa T; Konno S
    Int J Infect Dis; 2019 Oct; 87():54-59. PubMed ID: 31419482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
    Warrener P; Varkey R; Bonnell JC; DiGiandomenico A; Camara M; Cook K; Peng L; Zha J; Chowdury P; Sellman B; Stover CK
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4384-91. PubMed ID: 24841258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional Monoclonal Antibody Targeting
    Hebert W; DiGiandomenico A; Zegans M
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33147726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H; Katoh H; Kinoshita M; Shimizu M; Hamaoka S; Akiyama K; Naito Y; Sawa T
    Microbiol Immunol; 2016 Feb; 60(2):114-20. PubMed ID: 26696420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature.
    Thanabalasuriar A; Surewaard BG; Willson ME; Neupane AS; Stover CK; Warrener P; Wilson G; Keller AE; Sellman BR; DiGiandomenico A; Kubes P
    J Clin Invest; 2017 Jun; 127(6):2249-2261. PubMed ID: 28463232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.